Testing the Addition of the Drug Nivolumab after Surgery for Non-Small Cell Lung Cancer

June 20, 2016
EA5142
Lung Cancer
Maria Quejada, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst
 

To find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.

Sponsor: Eastern Cooperative Oncology Group (ECOG)

https://clinicaltrials.gov/ct2/show/NCT02595944
  • Over the age of 18
  • Must have undergone complete surgical resection of stage 1B, II or IIIA NSCLC
  • You must be registered to the Alliance A151216 study and have tumor mutation results
  • Must have completed and recovered from any adjuvant chemotherapy 2 or more weeks prior to randomization
10 years
Accepting Participants
Interventional
III
Kathy Seymour, RN, BSN
630-646-6075
630-646-6110
630-646-6072